Fonkozomib 3.5mg powder for injection
Ferron Par Pharmaceuticals
Ingredients in every vial
Each package contains
|ATC Level 1||L - Antineoplastic and immunomodulating agents|
|ATC Level 2||L01 - Antineoplastic Agents|
|ATC Level 3||L01X - Other Antineoplastic Agents in ATC|
18 YEARS OLD AND ABOVE
Dosage in relapsed multiple myeloma and mantle cell lymphoma. Recommended dosage The recommended dose of bortezomib is 1.3 mg/m2/dose administered as a 3 to 5 second bolus intravenous injection twice weekly for 2 weeks on days 1, 4, 8, and 11, followed by a 10-day rest period on days 12-21. This 3-week period is considered a treatment cycle. At least 72 hours should elapse between consecutive doses of bortezomib.. It is recommended that patients receive 2 additional cycles of bortezomib following a confirmation of a complete response. It is also recommended that responding patients who do not achieve a complete remission receive a total of 8 cycles of bortezomib therapy.
Bortezomib for injection is indicated for the treatment of multiple myeloma patients who have received at least 1 prior therapy and have demonstrated disease progression on the last therapy. Bortezomib for injection is indicated for the treatment of patients with mantle cell lymphoma who have received at least 1 prior therapy. Bortezomib in combination with melphalan and prednisone is indicated for the treatment of patients with previously untreated multiple myeloma who are not eligible for high-dose chemotherapy with bone marrow transplant.